---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-012148"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T01:05:03.254045+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vericel Q1 revenue up 4% to $36.1M; net loss widens to $7.1M; reaffirms FY2022 guidance

## Summary
- Total net revenue $36.1M (+4% YoY); MACI $26.0M, Epicel $9.9M, NexoBrid $0.2M.
- Net loss $7.1M ($0.15/share) vs $3.3M loss a year ago; non-GAAP adj. EBITDA $3.2M.
- Reaffirmed FY2022 guidance: revenue $178-189M, gross margin ~70%, adj. EBITDA margin ~21%.
- MACI and Epicel biopsies growing double-digit; NexoBrid BLA resubmission on track for mid-2022.
- Appointed Mike Gilligan as VP, MACI National Sales.

## SEC filing metadata
- accession: 0001628280-22-012148
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828022012148/0001628280-22-012148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828022012148/vcel-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-012148
- JSON: https://secwatch.observer/filing/0001628280-22-012148.json
- Plain text: https://secwatch.observer/filing/0001628280-22-012148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.